How “Old” Are You Really? Find Out at NattoPharma’s Booth at SSW 2017

Newly Recognized Tool From iHeart Determines “Internal Age” Via Aortic Stiffness

OSLO, NORWAY and METUCHEN, NJ (September 13, 2017) – NattoPharma, the world leaders in Vitamin K2 research and development, has confirmed and cultivated an understanding that K2 supports cardiovascular health by activating proteins that inhibit arterial calcification. So it is understandable that NattoPharma is excited to be teaming with a company that has pioneered a system that helps to determine one’s “internal age” by measuring aortic stiffness via pulse wave velocity (PWV). The iHeart system is the perfect complement to NattoPharma’s clinically validated cardiovascular and bone support ingredient, MenaQ7® Vitamin K2 as MK-7.

The iHeart system calculates one’s Internal Age, a measure of Aortic Stiffness relative to others the same age, using Aortic Pulse Wave Velocity (AoPWV). AoPWV is the speed a pulse wave travels down the aorta, the body’s largest blood vessel. AoPWV has been proven to be a powerful predictor for risk of heart disease, stroke and dementia, while Aortic Stiffness has been linked to inadequate dietary intakes, specifically Vitamin K2, as substantiated in population and clinical studies. iHeart proves a snapshot of current heart health and objectively shows benefit of Vitamin K2 supplementation.

“By analyzing the fingertip arterial pulse signal, our system calculates the aortic pulse wave velocity within 30 seconds, which then allows users to track the effects of lifestyle choices on their internal age,” says Dr. Jess Goodman, the creator of the iHeart system.  

A Canadian general practitioner and medical advisor at three long-term care facilities, Dr. Goodman is well aware of the importance of physical activity for health maintenance, he “wanted to provide a simple, easy-to-use metric that showed health benefit of regular exercise. Aortic stiffness served this purpose well, being a parameter proven to predict the risk of death from all causes and shown to improve with exercise.”

“Our 3-year cardiovascular study measured pulse wave velocity to determine that a nutritional dose of MenaQ7 improved arterial stiffness. And now the iHeart system provides a quick, non-invasive way to calculate one’s aortic pulse wave velocity, designating whether they could benefit from Vitamin K2 supplementation,” says Eric Anderson, SVP Global Marketing and Business Development.

iHeart will be at NattoPharma’s SupplySide West booth (P115) demonstrating this amazing technology, which is a perfect match for NattoPharma’s clinically proven and patented MenaQ7® Vitamin K2 as MK-7.  

Plan to come by to get your iHeart measurement. Visit www.goiheart.com to find out more about the iHeart system, and www.MenaQ7.com to learn more about this expert Vitamin K2 brand.    

# # #


About NattoPharma

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for

applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Metuchen, NJ. For more information, visit nattopharma.com.

About iHeart

VitalSines was founded by Dr. Jess Goodman to give people the ability to see health benefits from exercise, good diet, and stress management through health technology. Dr. Goodman has developed the iHeart System, a revolutionary method of analyzing the arterial pulse signal, objectively showing internal health changes related to Aortic Stiffness. The company is dedicated to providing people with devices and resources to optimize their health and wellness.  

For more information, please contact:

Kate Quackenbush, Director of Communications

NattoPharma USA, Inc.

Phone: 609-643-0749

E-mail: kate.quackenbush@nattopharma.com

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.

Subscribe

Documents & Links